ATEC Q3 2026 Earnings: Biologics Weakness Limits Revenue Growth

Alphatec Holdings, or ATEC (Nasdaq: ATEC), reported Q3 2026 revenue of $221.2 million, up 12.6% from $196.5 million, while its GAAP diluted loss per share narrowed to $0.03 from $0.19. Surgical revenue rose 14% to $202 million, but lower biologics attachment prevented approximately 20% case growth and 25% growth in new surgeon users from translating fully into revenue. Gross-margin expansion and controlled GAAP expenses produced an operating profit, although interest and other expenses kept the company in a GAAP net loss.

Core Financial Results

Gross profit increased faster than revenue, lifting GAAP gross margin by 160 basis points to 71.5%. GAAP operating expenses rose only about 1.2% to $155.0 million, helped by litigation-related expenses falling to $0.6 million from $6.5 million, allowing ATEC to move from an operating loss to a $3.2 million operating profit.

Adjusted results also improved: adjusted EBITDA increased 46.5%, and its margin expanded by 400 basis points. The quarter nevertheless ended with a $5.5 million GAAP net loss because operating income was more than offset by interest and other expenses.

Non-GAAP results exclude items including stock-based compensation, acquired-intangible amortization, litigation costs, non-cash interest expense, and tax-rate adjustments. These exclusions account for the substantial difference between the GAAP net loss and non-GAAP net income.

Strong Procedure Demand Did Not Fully Translate Into Revenue

Surgical revenue increased by $25 million to $202 million, with surgical hardware contributing $26 million of growth and rising 17%. Because hardware contributed slightly more than the total surgical revenue increase on the rounded reported figures, other surgical revenue categories were a modest net offset.

Management identified lower biologics attachment as the principal reason revenue fell short of its own expectations. This explains why approximately 20% case-volume growth and 25% growth in new surgeon users produced slower increases of 14% in surgical revenue and 13% in total revenue.

The operational demand indicators remained favorable, but the quarter showed that case growth alone does not determine revenue growth. ATEC must also increase the amount of biologics revenue attached to each procedure. Management described improving biologics execution as a priority while continuing to build toward the longer-term OsteoAdapt opportunity.

Profitability, Cash Flow, and the Balance Sheet

ATEC’s GAAP operating margin improved to approximately 1.5% from negative 8.1%. Non-GAAP gross margin also rose to 71.9% from 70.1%, while adjusted EBITDA margin reached 17.3%. Lower litigation expenses supported the GAAP improvement, while the adjusted figures indicate that the underlying gross-profit increase also outpaced adjusted operating-expense growth.

The company did not yet reach GAAP net profitability. Total other expense was $10.7 million, including $4.1 million of cash interest expense and $6.5 million of non-cash interest expense, compared with only $3.2 million of operating income. This resulted in a $7.5 million pretax loss and a $5.5 million net loss after a $2.0 million income-tax benefit.

Free cash flow was positive at $6 million, and ATEC said trailing-12-month free cash flow remained positive. However, cash and cash equivalents declined to $79.9 million at September 30 from $160.8 million at the end of 2025. Over the same period, inventory increased 22.1% to $206.9 million, accounts receivable rose 13.9% to $110.8 million, and short-term debt fell to $5.3 million from $64.5 million.

Full-Year 2026 Guidance

ATEC now expects approximately $862 million of 2026 revenue, representing about 13% growth, including $789 million of surgical revenue and $73 million of EOS revenue. The company also targets $137 million of adjusted EBITDA and $10 million of free cash flow. The supplied release does not state the previous outlook, so the direction or size of any guidance revision cannot be determined.

Based on reported nine-month results, the fourth quarter must contribute approximately $235.2 million of revenue and $42.1 million of adjusted EBITDA to reach the full-year targets.

The implied fourth-quarter adjusted EBITDA margin is approximately 17.9%, modestly above the 17.3% reported in Q3. ATEC did not provide a GAAP reconciliation for its forward-looking non-GAAP measures because some adjustments cannot be reasonably predicted.

Recent Insider Transactions

ATEC’s insider data showed 642,072 shares purchased and 194,218 shares sold across the reported six-month period, for net purchases of 447,854 shares. The latest 10 reported transactions consisted of one purchase, two sales, and seven stock-award grants; all were reported as direct holdings.

Stock-award grants are compensation-related transactions and should not be interpreted as market purchases. The reported six-month net-purchase figure also covers more transactions than the 10 most recent entries shown above.

Risks Investors Need to Watch

• Biologics attachment remains an execution issue. If ATEC cannot improve biologics utilization per procedure, strong case and surgeon growth may continue to produce slower revenue growth.
• The full-year outlook requires a sequential step-up. Reaching guidance requires approximately $235.2 million of Q4 revenue and $42.1 million of adjusted EBITDA, both above Q3 levels.
• Financing costs continue to delay GAAP profitability. Interest and other expenses exceeded operating income in Q3, leaving ATEC with a net loss despite turning profitable at the operating level.
• Cash and inventory trends require monitoring. Cash declined substantially from year-end while inventory increased, making sustained positive free cash flow and effective working-capital management important.

Summary

ATEC’s Q3 2026 results combined double-digit revenue growth, substantial margin expansion, an operating profit, and positive free cash flow. The central issue was lower biologics attachment, which limited revenue conversion despite strong procedure, hardware, and surgeon-adoption trends. The next key measures are whether biologics execution improves and whether ATEC can deliver the sequential revenue and adjusted EBITDA increases needed to reach its full-year outlook.